Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ardelyx Inc.

www.ardelyx.com

Latest From Ardelyx Inc.

Zelnorm Returning To US Market With Broad IBS-C Indication

US FDA limiting use of Zelnorm, originally pulled from the market in 2007 by its then-sponsor Novartis, to adult women who are at low CV risk, but tegaserod is not restricted to patients who are severely symptomatic for IBS-C. 
Approvals Gastrointestinal

Keeping Track: AstraZeneca Wins Approval For Lumoxiti, AbbVie Expands Label For Venclexta With MRD Data, and FDA Delays Acorda's Inbrijia NDA

The latest drug development news and highlights from our US FDA Performance Tracker.
Drug Review Regulation

US FDA Reviews IBS-C Candidates Both New (Tenapanor) And Old (Tegaserod)

Ardelyx touts tenapanor's novel mechanism, favorable safety profile; advisory committee announcement reveals US Worldmeds’ bid to revive Novartis’ withdrawn Zelnorm.
Drug Review Gastrointestinal

Key Drug Launches To Plan For In 2019

Around three dozen key late-stage products could reach their first markets in 2019, according to a recent report from Informa Pharma's Biomedtracker. Company execs may need to plan for the disruptive potential of this group of new medicines on established markets and standards of care.

Approvals Launches
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Cardiovascular
  • Gastrointestinal
  • Metabolic Disorders
  • Renal System
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Ardelyx Inc.
  • Senior Management
  • Michael G Raab, Pres. & CEO
    Mark Kaufmann, CFO
    David Rosenbaum, Chief Dev. Officer
  • Contact Info
  • Ardelyx Inc.
    Phone: (510) 745-1700
    34175 Ardenwood Blvd.
    Fremont, CA 94555
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register